Quest Diagnostics Incorporated · DGX · Next earnings

Quest Diagnostics Incorporated reports Tuesday, Oct 20, 2026

DGX reports before market open with consensus EPS at $2.85 and revenue at $3.04B. Last quarter: Quest Diagnostics Beats on Volume and AI Automation, Raises Full-Year Guidance

Reports Before market open30 days awayDate estimated Healthcare

What the street expects

Consensus for the coming report
Consensus EPS $2.85 Calendar consensus
Consensus revenue $3.04B Calendar consensus
Report date Oct 20, 2026 Tuesday, date estimated
Session Before market open 30 days away

Where DGX left off: FY2026 Q2

Full report

Quest Diagnostics Beats on Volume and AI Automation, Raises Full-Year Guidance

EPS surprise +10.6% Reported $3.12 vs $2.82
Revenue surprise +2.4% Reported $3.04B vs $2.97B
Stock move +8.6% Event window
Subsequent drift +3.0% Up to 20 sessions

Full-year 2026 revenue guidance raised from $11.78-$11.9B (prior quarter) to $11.95-$12.05B, a $170M increase at the midpoint. Adjusted EPS guidance raised from $9.58-$9.78 to $9.97-$10.17, a $0.39 increase at the midpoint. Capex guidance now explicitly stated at $550M. The company has raised guidance in both Q1 and Q2 of fiscal 2026.

What to watch on the call

Carried forward from the last transcript

Risks management flagged

  • ACA subsidy expiration could create approximately 30 basis points of revenue pressure.
  • Higher fuel costs expected in the second half.
  • Uncertainty around PAMA reimbursement rates and RESULTS Act outcomes.
  • Possible bad-debt exposure in hospital Co-Lab relationships, though not yet observed.
  • Margin compression from Nova expenses and mix effects from lower-margin routine tests.

Questions analysts left open

  • Hospital channel performance, pipeline of Co-Lab deals, and bad-debt risk
  • Impact of ACA subsidy changes on revenue outlook
  • Margin outlook, especially Nova expense trajectory and fuel cost headwinds
  • Pricing trends and reimbursement environment for labs
  • PAMA and potential cuts or delays in lab reimbursement rates

Ask FN2 about DGX next report

Transcript, numbers and history already loaded
What should I watch for in DGX's next earnings report?How did DGX guide last quarter, and is consensus above or below that?Give me the bull and bear case going into DGX earnings.

Free account. Your question opens in FN2 with this report's transcript and numbers attached.

Get the DGX recap when the next report posts

One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.

Recent DGX quarters

All DGX earnings
+8.6%FY2026 Q2

Sources

  1. FN2 corporate events calendar, resolved from the earnings calendar feed
  2. FN2 earnings calendar analyst consensus
  3. Earnings call transcript analysis, FY2026 Q2

Methodology

The report date comes from FN2's resolved corporate-events calendar and is marked estimated until the company confirms it. Consensus figures are the calendar's latest analyst estimates for the fiscal period and are not an FN2 forecast.

Risks and open questions are carried forward verbatim from FN2's structured analysis of the previous earnings call. Missing values stay missing and are never estimated.

By FN2 Research · Updated . For educational purposes only; not investment advice.